Super-resolution microscopy for immune checkpoint inhibitors diagnostics
NANODIAGNOSTIC aims to translate super-resolution microscopy techniques into clinical tools for cancer diagnostics, enhancing patient stratification for effective immunotherapy.
Projectdetails
Introduction
In the last decade, super-resolution microscopy techniques have emerged as powerful quantitative tools for biology. They have capabilities to visualize single molecules at the nanoscale, opening the door to study biological processes at a level not accessible before.
Project Background
In the ERC StG NANOSTORM, we showed the potential of these techniques, providing new fundamental knowledge on the mechanism and design of new targeted therapies. However, some of the methods we developed have the potential to be translated into applied clinical diagnostic tools.
Project Goals
In NANODIAGNOSTIC, we would offer a proof-of-concept of the application of super-resolution microscopy and single-molecule imaging for cancer diagnostics, with a focus on patient stratification for immunotherapy.
Immunotherapy Context
Novel advances in immunotherapies have brought the development of immune checkpoint inhibitors (ICI) that re-activate the immune system against the tumor. Despite the high success of these therapies, there is one main challenge:
- They are only effective on a limited portion of patients.
- Current diagnostic approaches are not capable of stratifying patients successfully.
Expected Outcomes
NANODIAGNOSTIC will translate advanced optical methods from an academic setting to the clinic and holds great potential to provide new diagnostic methods to improve the outcome of immunotherapy.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 150.000 |
Totale projectbegroting | € 150.000 |
Tijdlijn
Startdatum | 1-12-2022 |
Einddatum | 31-5-2024 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- TECHNISCHE UNIVERSITEIT EINDHOVENpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Nano-assisted digitalizing of cancer phenotyping for immunotherapyThe ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes. | ERC Consolid... | € 1.993.875 | 2023 | Details |
Nanobodies blocking immunosuppressive unexplored proteins from the tumor endothelium to promote anti-tumor immune responseThis project aims to develop novel nanobody therapeutics targeting unexplored immunosuppressive genes in endothelial cells to enhance anti-tumor immunity in non-small cell lung cancer. | ERC Proof of... | € 150.000 | 2025 | Details |
Allosteric modulation of immune checkpoint complexes as a new mode of therapeutic intervention in immunotherapyThe project aims to develop novel Nanobodies as safe and effective modulators of immune checkpoint complexes for cancer and autoimmune diseases, potentially outperforming current therapies. | ERC Advanced... | € 2.499.674 | 2024 | Details |
Precision Diagnostics for Predicting Therapy Response to Bispecific AntibodiesThis project aims to develop a precision diagnostic tool that predicts responses to bispecific antibody therapies by mapping single-cell immune interactions in children with acute lymphoblastic leukemia. | ERC Proof of... | € 150.000 | 2025 | Details |
Development of a nanobody-based, slide-free approach for 3D-Histological analysis of the spatial tumor microenvironment using lightsheet imagingThis project aims to revolutionize cancer histology through a nanobody-based 3D-histopathology approach, enabling rapid, spatially accurate analysis of tumor microenvironments for improved diagnosis and patient stratification. | ERC Proof of... | € 150.000 | 2025 | Details |
Nano-assisted digitalizing of cancer phenotyping for immunotherapy
The ImmunoChip project aims to develop a microfluidic device that analyzes cancer-immunity interactions to predict patient responses to immunotherapy, enhancing treatment efficacy and outcomes.
Nanobodies blocking immunosuppressive unexplored proteins from the tumor endothelium to promote anti-tumor immune response
This project aims to develop novel nanobody therapeutics targeting unexplored immunosuppressive genes in endothelial cells to enhance anti-tumor immunity in non-small cell lung cancer.
Allosteric modulation of immune checkpoint complexes as a new mode of therapeutic intervention in immunotherapy
The project aims to develop novel Nanobodies as safe and effective modulators of immune checkpoint complexes for cancer and autoimmune diseases, potentially outperforming current therapies.
Precision Diagnostics for Predicting Therapy Response to Bispecific Antibodies
This project aims to develop a precision diagnostic tool that predicts responses to bispecific antibody therapies by mapping single-cell immune interactions in children with acute lymphoblastic leukemia.
Development of a nanobody-based, slide-free approach for 3D-Histological analysis of the spatial tumor microenvironment using lightsheet imaging
This project aims to revolutionize cancer histology through a nanobody-based 3D-histopathology approach, enabling rapid, spatially accurate analysis of tumor microenvironments for improved diagnosis and patient stratification.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors. | EIC Accelerator | € 2.496.112 | 2024 | Details |
Functional chemical reprogramming of cancer cells to induce antitumor immunityThe RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments. | EIC Pathfinder | € 2.966.695 | 2024 | Details |
RESTORING IMMUNITY CONTROL OF GI CANCERSTIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization. | EIC Transition | € 2.007.750 | 2025 | Details |
Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samplesThe NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs. | EIC Transition | € 2.499.999 | 2025 | Details |
On-chip tomographic microscopy: a paraDIgm Shift for RevolUtionizing lab-on-a-chiP bioimaging technologyDISRUPT aims to revolutionize biomedical imaging with a novel lab-on-chip technology for cost-effective, high-resolution cancer detection and diagnostics using integrated tomographic microscopy and AI. | EIC Pathfinder | € 3.018.312 | 2022 | Details |
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.
The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors.
Functional chemical reprogramming of cancer cells to induce antitumor immunity
The RESYNC consortium aims to revolutionize cancer immunotherapy by reprogramming cancer cells into antigen-presenting dendritic cells using small molecules for personalized and safer treatments.
RESTORING IMMUNITY CONTROL OF GI CANCERS
TIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization.
Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samples
The NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs.
On-chip tomographic microscopy: a paraDIgm Shift for RevolUtionizing lab-on-a-chiP bioimaging technology
DISRUPT aims to revolutionize biomedical imaging with a novel lab-on-chip technology for cost-effective, high-resolution cancer detection and diagnostics using integrated tomographic microscopy and AI.